» Articles » PMID: 35586377

Research Progress on Circulating Tumor Cells of Hepatocellular Carcinoma

Overview
Journal J Interv Med
Specialty General Medicine
Date 2022 May 19
PMID 35586377
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cells (CTCs) are the cells released from the primary tumor and found in the peripheral blood, which can colonize and develop at a distance through blood circulation. At present, the commonly used separation and detection methods of CTCs are mainly divided into physical methods, biological methods, and microfluidic chip-based methods. Monitoring CTC count and cell phenotype is of great significance for early screening and diagnosis of hepatocellular carcinoma (HCC). Moreover, the CTC count and cell phenotype are related to assessing the clinical efficacy of the treatment of HCC and the clinical stage of HCC patients. The CTCs count is also closely related to the overall survival, progression-free survival, and postoperative recurrence of patients with HCC.

Citing Articles

The capture of circulating tumor cells by Labyrinth system as a tool for early stage lung cancer detection.

Jin P, Li H, Xie M, Tang J, Zou S, Wang R Front Oncol. 2024; 14:1474015.

PMID: 39540154 PMC: 11557529. DOI: 10.3389/fonc.2024.1474015.


Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.

Nie C, Shaw I, Chen C J Pharm Anal. 2024; 13(12):1429-1451.

PMID: 38223444 PMC: 10785256. DOI: 10.1016/j.jpha.2023.08.009.


Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review.

Orrapin S, Udomruk S, Lapisatepun W, Moonmuang S, Phanphaisarn A, Phinyo P Cancers (Basel). 2022; 14(14).

PMID: 35884432 PMC: 9322939. DOI: 10.3390/cancers14143373.

References
1.
Kang Y, Pantel K . Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013; 23(5):573-81. PMC: 3667710. DOI: 10.1016/j.ccr.2013.04.017. View

2.
Rau K, Liu C, Hsiao Y, Hsiao K, Wang T, Hung W . Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020; 9(1). PMC: 7019972. DOI: 10.3390/jcm9010188. View

3.
Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K . Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013; 133(9):2165-71. DOI: 10.1002/ijc.28230. View

4.
Li J, Liao Y, Ran Y, Wang G, Wu W, Qiu Y . Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer. BMC Pulm Med. 2020; 20(1):274. PMC: 7576719. DOI: 10.1186/s12890-020-01314-4. View

5.
Lee Y, Guan G, Bhagat A . ClearCell® FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells. Cytometry A. 2018; 93(12):1251-1254. DOI: 10.1002/cyto.a.23507. View